Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation

David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Borghaei, Dave S B Hoon, Stephen V Liu, Patrick C Ma, Rana R McKay, Trisha Wise-Draper, John Marshall, George W Sledge, David Spetzler, Hao Zhu

Research output: Contribution to journalLetterpeer-review

Abstract

Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with mutation burden or long-term survivors after immunotherapies across cancer entities. Thus, immunological stratification of tumors has limited bearing on the immunogenicity of tumors or immunotherapy outcomes.

Original languageEnglish
Pages (from-to)1985-1987
Number of pages3
JournalCancer Cell
Volume42
Issue number12
Early online dateNov 13 2024
DOIs
StatePublished - Dec 9 2024

Keywords

  • B7-H1 Antigen/immunology
  • Humans
  • Immune Checkpoint Inhibitors/therapeutic use
  • Immunotherapy/methods
  • Lymphocyte Activation
  • Lymphocytes, Tumor-Infiltrating/immunology
  • Mutation
  • Neoplasms/immunology
  • Programmed Cell Death 1 Receptor/antagonists & inhibitors

Fingerprint

Dive into the research topics of 'Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation'. Together they form a unique fingerprint.

Cite this